Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
AVIR
vs
S&P 500
AVIR
S&P 500
Over the past 12 months, AVIR has significantly outperformed S&P 500, delivering a return of +66% compared to S&P 500's +17% growth.
Stocks Performance
AVIR vs S&P 500
Performance Gap
AVIR vs S&P 500
Performance By Year
AVIR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Atea Pharmaceuticals Inc
Glance View
Atea Pharmaceuticals is a biotech company focused on antiviral medicines. It works on small-molecule drugs taken by mouth that are designed to stop viruses from copying themselves inside the body. The company’s main research has centered on treatments for hepatitis C and other serious viral infections. Atea does not sell a broad menu of commercial drugs. It makes money mainly through drug development work, such as research collaborations, licensing deals, and future payments that could come if one of its drug candidates reaches approval and is marketed. Its customers and partners are usually large pharmaceutical companies, research collaborators, and eventually doctors and patients if a medicine is approved. What makes Atea’s business different is that it sits in the high-risk, high-reward part of the drug industry. Instead of making finished products today, it tries to build a pipeline of antiviral candidates that can become prescription medicines later. That means its value comes from scientific progress, patent protection, and the chance to turn lab research into approved treatments.
